EP1517695A4 - Osteopontin, oligodendrocytes and myelination - Google Patents

Osteopontin, oligodendrocytes and myelination

Info

Publication number
EP1517695A4
EP1517695A4 EP03742164A EP03742164A EP1517695A4 EP 1517695 A4 EP1517695 A4 EP 1517695A4 EP 03742164 A EP03742164 A EP 03742164A EP 03742164 A EP03742164 A EP 03742164A EP 1517695 A4 EP1517695 A4 EP 1517695A4
Authority
EP
European Patent Office
Prior art keywords
myelination
osteopontin
oligodendrocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03742164A
Other languages
German (de)
French (fr)
Other versions
EP1517695A2 (en
Inventor
Jean Merrill
Su-Fen Pu
Olga Khorkova
Zhongqi Ji
Fernando Camacho
Steve Busch
Min Wang
Ting Chen
Robert J Dinerstein
Zhengbin Yao
Yangde Chen
Xin Zhang
Karen Chandross
Lan Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0224017.4A external-priority patent/GB0224017D0/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of EP1517695A2 publication Critical patent/EP1517695A2/en
Publication of EP1517695A4 publication Critical patent/EP1517695A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/585—Integrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Psychiatry (AREA)
EP03742164A 2002-06-25 2003-06-24 Osteopontin, oligodendrocytes and myelination Withdrawn EP1517695A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39103502P 2002-06-25 2002-06-25
US391035P 2002-06-25
GBGB0224017.4A GB0224017D0 (en) 2002-06-25 2002-10-16 Osteopontin oligodendrocytes and myelination
GB0224017 2002-10-16
PCT/US2003/019864 WO2004001014A2 (en) 2002-06-25 2003-06-24 Osteopontin, oligodendrocytes and myelination

Publications (2)

Publication Number Publication Date
EP1517695A2 EP1517695A2 (en) 2005-03-30
EP1517695A4 true EP1517695A4 (en) 2010-09-01

Family

ID=30001991

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03742164A Withdrawn EP1517695A4 (en) 2002-06-25 2003-06-24 Osteopontin, oligodendrocytes and myelination

Country Status (11)

Country Link
EP (1) EP1517695A4 (en)
JP (1) JP2005535313A (en)
CN (1) CN1662249A (en)
AU (1) AU2003278205B2 (en)
BR (1) BR0312042A (en)
CA (1) CA2489905A1 (en)
IL (1) IL165932A0 (en)
MX (1) MXPA04012803A (en)
NO (1) NO20045560L (en)
RU (1) RU2005101633A (en)
WO (1) WO2004001014A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005238092B2 (en) * 2004-05-03 2010-06-17 Peter Maccallum Cancer Institute Methods for stem cell expansion and differentiation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
WO2002092122A2 (en) * 2001-05-17 2002-11-21 Applied Research Systems Ars Holding N.V. Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2003046135A2 (en) * 2001-11-21 2003-06-05 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
WO2002092122A2 (en) * 2001-05-17 2002-11-21 Applied Research Systems Ars Holding N.V. Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2003046135A2 (en) * 2001-11-21 2003-06-05 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHABAS DOROTHEE ET AL: "The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US LNKD- DOI:10.1126/SCIENCE.1062960, vol. 294, no. 5547, 23 November 2001 (2001-11-23), pages 1731 - 1735, XP002299870, ISSN: 0036-8075 *
ELLISON J A ET AL: "MATRIX REMODELING AFTER STROKE DE NOVO EXPRESSION OF MATRIX PROTEINS AND INTEGRIN RECEPTORS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US LNKD- DOI:10.1111/J.1749-6632.1999.TB07996.X, vol. 890, 1 January 1999 (1999-01-01), pages 204 - 222, XP001029484, ISSN: 0077-8923 *
JANSSON MARIANNE ET AL: "Cutting edge: Attenuated experimental autoimmune encephalomyelitis is Eta-1/osteopontin-deficient mice", JOURNAL OF IMMUNOLOGY, vol. 168, no. 5, 1 March 2002 (2002-03-01), pages 2096 - 2099, XP002591250, ISSN: 0022-1767 *
WANG X ET AL: "DELAYED EXPRESSION OF OSTEOPONTIN AFTER FOCAL STROKE IN THE RAT", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 18, no. 6, 15 March 1998 (1998-03-15), pages 2075 - 2083, XP001029483, ISSN: 0270-6474 *

Also Published As

Publication number Publication date
CA2489905A1 (en) 2003-12-31
JP2005535313A (en) 2005-11-24
AU2003278205A1 (en) 2004-01-06
MXPA04012803A (en) 2005-06-08
BR0312042A (en) 2005-05-24
RU2005101633A (en) 2005-06-10
IL165932A0 (en) 2006-01-15
EP1517695A2 (en) 2005-03-30
WO2004001014A3 (en) 2004-12-29
WO2004001014A2 (en) 2003-12-31
NO20045560L (en) 2004-12-20
CN1662249A (en) 2005-08-31
AU2003278205B2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
PL375599A1 (en) Multi-purpose polymers, methods and compositions
HK1073070A1 (en) Novel biomaterials, their preparation and use
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (en) Compounds, methods and compositions
AU2003236527A8 (en) Compounds, compositions, and methods
EP1513820A4 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
EP1481096A4 (en) Surface modification, linker attachment, and polymerization methods
AU2003299612A8 (en) Compounds, compositions and methods
AU2002366630A1 (en) Elastomer composites, elastomer blends and methods
EP1511734A4 (en) Compounds, compositions, and methods
GB0114399D0 (en) Substrates, biomaterials and methods
PL369644A1 (en) Spiro and dispiro -1,2,4-trioxalane antimalarials
AU2003277079A8 (en) Compounds, compositions, and methods
GB0202871D0 (en) Assays,methods and means
AU2003217565A8 (en) Polydioxaborines, their monomers and their preparation
AU2003267169A8 (en) Compounds, compositions and methods
AU2003300031A8 (en) Compounds, compositions, and methods
GB0228525D0 (en) Polymers and their use
EP1517695A4 (en) Osteopontin, oligodendrocytes and myelination
HK1068458A1 (en) Switch pushing method, and switch
GB0305089D0 (en) Composition, use and process
GB0224017D0 (en) Osteopontin oligodendrocytes and myelination
EP1660088A4 (en) Pyridomorphinans, pyridazinomorphinans and use thereof
GB0229445D0 (en) Process,composition and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17P Request for examination filed

Effective date: 20050629

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20050629

Extension state: LV

Payment date: 20050629

Extension state: LT

Payment date: 20050629

Extension state: AL

Payment date: 20050629

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEE, LAN

Inventor name: CHANDROSS, KAREN

Inventor name: ZHANG, XIN

Inventor name: CHEN, YANGDE

Inventor name: YAO, ZHENGBIN

Inventor name: DINERSTEIN, ROBERT, J.

Inventor name: CHEN, TING

Inventor name: WANG, MIN

Inventor name: BUSCH, STEVE

Inventor name: CAMACHO, FERNANDO

Inventor name: JI, ZHONGQI

Inventor name: KHORKOVA, OLGA

Inventor name: PU, SU-FEN

Inventor name: MERRILL, JEAN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20100720BHEP

Ipc: G01N 33/567 20060101ALI20100720BHEP

Ipc: G01N 33/53 20060101ALI20100720BHEP

Ipc: C12Q 1/70 20060101ALI20100720BHEP

Ipc: C12Q 1/00 20060101ALI20100720BHEP

Ipc: A61K 39/395 20060101ALI20100720BHEP

Ipc: A61K 38/00 20060101AFI20050103BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100826